Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.75 – $2.40
58% from low
Exchange
OTC Link
CS
Borrow rate
1.00%
Moderate
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $21.9M | $24.1M | $32.4M | $41.3M | $31.8M | $40.2M | $46.9M | $38.7M |
| Cost of revenue | $10.2M | $15.9M | $21.7M | $23.4M | $13.6M | $16.3M | $17.0M | $14.6M |
| Gross profit | $11.7M | $8.2M | $10.7M | $17.9M | $18.2M | $23.9M | $29.9M | $24.1M |
| Gross margin | 53.4% | 34.0% | 33.1% | 43.4% | 57.3% | 59.4% | 63.8% | 62.3% |
| R&D | $2.1M | $2.8M | $2.8M | $1.9M | $703.0K | $636.0K | $676.0K | $642.0K |
| Operating income | −$12.1M | −$23.9M | −$26.6M | −$11.7M | −$3.8M | $2.8M | $8.1M | $4.1M |
| EBITDA | −$8.6M | −$21.7M | −$20.1M | −$1.3M | −$2.3M | $3.8M | $8.4M | $4.8M |
| Net income | −$12.2M | −$26.6M | −$26.2M | −$14.7M | −$5.9M | $802.0K | $6.7M | $24.6M |
| Net margin | -55.7% | -110.6% | -80.9% | -35.7% | -18.4% | 2.0% | 14.3% | 63.5% |
| EPS (diluted) | -4.33 | -7.11 | -6.50 | -3.57 | -1.38 | 0.18 | 0.40 | 0.89 |
Annual figures · source: Financial Modeling Prep
INTERPACE BIOSCIENCES INC
No one on the platform currently holds IDXG.
No tracked institution reports a position in IDXG as of their last filing.
| Execution date | Ratio |
|---|---|
| 2020-01-15 | 1-for-10reverse |
| 2016-12-29 | 1-for-10reverse |
No one on the platform has traded IDXG yet.
| $2M |
| — |
| RMSLREMSleep Holdings, Inc. | $0.00 | -4.17% | $4M | — |
| RNVARennova Health, Inc. | $0.00 | +0.00% | $4M | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$IDXG selling on a 0.14c rise? Come on, man?! Let's get back to $2+
View on StockTwits ↗$IDXG I think everyome has left the building. Small buys and sells killing the price. Lets gobble up those cheap shares!
View on StockTwits ↗$IDXG Please just sell the company. Been in this so long.
View on StockTwits ↗$IDXG From the POV of 12 months ago? This was a spectacular quarter. The transition from post PancraGen to thyroid only has been spectacular. The elimination of the debt? A gigantic leap forward. Increased thyroid revenues? Reductiomn of costs? All spot on. From the perspective of 3 months ago? Mildly disappointing. The good news is that they maintained their guidance and margins are improving. But the $9MM.X in revenue and the $1.6MM in EBITDA were a touch light. Was hoping for $2.0MM in EBITDA to make a compelling story for a sale. And the $9MM.X in revenue equates to $36MM meaning they have to pick up the pace to meet guidance. Have felt that we need at least 5 clean thyroid quarters before IDXG can be sold. We're now at 3. Hoping Q2 is closer to $10MM in revenue than $9MM
View on StockTwits ↗$IDXG Have about three weeks until they announce Q1 earnings. All signs are pointing up. The debt is paid. Revenues are up. They are now a "clean thyroid company". This is the first "clean" Q1 where it's all thyroid. They mentioned increased efficiencies which means that gross margins should grow from an already strong base. For me? The big question is EBITDA. Q4 had $1.7MM Can Q1 break $2MM in EBITDA? If it does? IMHO it's off to the races. Project that to $9MM.X annually with sales growth and increased efficiencies? At 10 EBITDA that would mean over $3.
View on StockTwits ↗$IDXG alittle sideways with another climb up please. 🙏 📈
View on StockTwits ↗$IDXG STOP! What are you all doing?? Stop selling! Let it keep climbing!
View on StockTwits ↗$IDXG I have owned this for so long, and i thought my breakeven was $3. I just looked, and it's $3.94. Ugh! Still
View on StockTwits ↗$IDXG https://ir.interpace.com/sec-filings-email/content/0001493152-26-005161/ownership.html
View on StockTwits ↗$IDXG Really good write-up that perfectly summarizes IDXG's present situation. So if you want to bring your IDXG knowledge up to date or just discover IDXG, this is required reading. https://everyticker.com/quote/IDXG/analysis/interpace-biosciences-restructuring-for-a-thyroid-focused-future-after-pancragen-loss-otcqx-idxg
View on StockTwits ↗$IDXG Prior to uplisting IDXG would need some sort of a deal announced. With 84% concentrated in the 2 PE firms and 5% to a 3rd sharehodler, I doubt that the remaining 11% is spread to the requisite amount of shareholders. Dates to be aware of March 31 and May 15. Annual report is relased on March 31 and Q1 on May 15. Don't think that they would announce any deal prior to the annual report and audit. But before May 15? That would be likely IMHO in that they would be reporting how much cash they have on hand and without debt? It could be substantial.
View on StockTwits ↗$IDXG Uplisting requires sustained bid price above $4.X, minimum shareholders' equity, and market maker support, which IDXG is addressing through balance sheet cleanup (now debt-free). Past delays and microcap volatility could push it beyond early 2026; investors should watch SEC filings for Form 10-Q/10-K updates or formal applications
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Trading at 0.2× sales vs its 0.4× historical median P/S.
Fair value ≈ $4.90 · price $1.70 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.